CARANX MEDICAL
Description
Caranx Medical is revolutionizing Transcatheter Aortic Valve Implantation (TAVI) with its cutting-edge TAVIPILOT system. This autonomous robotic solution is set to make TAVI procedures more accessible, precise, and consistent, much like the impact the Da Vinci robot had in surgery.
TAVIPILOT is valve-agnostic and designed to simplify TAVI, reducing risks and expanding access, especially in underserved markets. Complementing this is TAVIPILOTsoft, a standalone AI-driven software that enhances TAVI by ensuring real-time, precise valve placement. It operates independently of the robot, boosting procedural safety and reducing complications, making TAVI safer and more accessible even in low-volume centers.
TAVIPILOT Robot:This autonomous robotic system is designed to double surgical capacity by enabling a single specialist to perform TAVI procedures with unmatched precision and consistency. By simplifying the complex steps of valve placement, TAVIPILOT Robot reduces the need for multiple specialists and minimizes the risks associated with the procedure. First-in-human trials are scheduled for 2025, marking a significant step toward revolutionizing TAVI procedures.
TAVIPILOT Soft: TAVIPILOT Soft is a powerful AI-driven imaging software that enhances TAVI procedures by providing real-time, millimetric accuracy in valve placement. Built on the world’s largest TAVI database, this software operates independently or in conjunction with the TAVIPILOT Robot, boosting procedural safety and reducing complications. Its commercialization is set to begin in 2025, offering a transformative solution for improving outcomes in TAVI, especially in low-volume centers.
First-in-human trials for TAVIPILOT Robot are set for 2025, with TAVIPILOT Soft commercialization beginning the same year.
